455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

455.45

-0.62%↓

SANES

9.402

-0.61%↓

SAF

276.5

-1.67%↓

BBVA

17.955

-1.45%↓

BNP

81.05

-0.92%↓

Home・Akciju saraksts・Ipsen SA.

Ipsen SA.

Slēgts

SektorsFinanšu

157.2 3.69

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

154.8

Max

158.9

Galvenie mērījumi
By Trading Economics
Ienākumi	-225M 110M
Pārdošana	36M 1.9B
P/E Sektora vidējais	27.842 54.484
Dividenžu ienesīgums	0.94
Peļņas marža	5.899
Darbinieki	5,535
EBITDA	-171M 466M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-7.51% downside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.94% 4.92%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	866M 12B
Iepriekšējā atvēršanas cena	153.51
Iepriekšējā slēgšanas cena	157.2

Ziņu noskaņojums

By Acuity

48%

52%

161 / 441 Rangs Finance

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

99.85 / 104 Atbalsts un pretestība

Ipsen SA. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. marts 17:33 UTC

Galvenie ziņu notikumi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026. g. 27. marts 17:00 UTC

Galvenie ziņu notikumi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026. g. 27. marts 16:03 UTC

Galvenie ziņu notikumi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026. g. 27. marts 14:50 UTC

Galvenie tirgus virzītāji

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

2026. g. 27. marts 14:37 UTC

Iegādes, apvienošanās, pārņemšana

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

2026. g. 27. marts 14:29 UTC

Galvenie ziņu notikumi

EU Finance Ministers Tally Economic Hit of Iran War -- Update

2026. g. 27. marts 14:16 UTC

Galvenie ziņu notikumi

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

2026. g. 27. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 19:16 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026. g. 27. marts 19:07 UTC

Tirgus saruna

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026. g. 27. marts 19:04 UTC

Tirgus saruna

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026. g. 27. marts 19:03 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 19:02 UTC

Tirgus saruna

Galvenie ziņu notikumi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026. g. 27. marts 18:12 UTC

Tirgus saruna

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026. g. 27. marts 17:36 UTC

Galvenie ziņu notikumi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026. g. 27. marts 17:34 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026. g. 27. marts 17:29 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026. g. 27. marts 16:38 UTC

Tirgus saruna

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026. g. 27. marts 16:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026. g. 27. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 15:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin Says Iran War Raising Economic Uncertainty

2026. g. 27. marts 14:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

2026. g. 27. marts 14:26 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

2026. g. 27. marts 14:14 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 14:14 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Ipsen SA. Prognoze

Cenas mērķis

By TipRanks

-7.51% uz leju

Prognoze 12 mēnešiem

Vidējais 141.33 EUR -7.51%

Augstākais 155 EUR

Zemākais 132 EUR

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ipsen SA. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ipsen SA. — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

99.85 / 104Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

161 / 441 Rangs Finanšu

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.